Media Newsroom of

TGV

United States
Website: http://tgv-inhalonix.com/
TGV

Bacterial and fungal respiratory infections are the main causes of  mortality in patients with cystic fibrosis.  Inhaled antibiotics play a pivotal role in managing these infections as the drugs are delivered directly to the lungs.

Despite these advancements, much of the bacteria that cause lung infections in cystic fibrosis patients  has grown resistant to traditional antibiotics, rendering most currently available antimicrobials useless and ineffective. Furthermore, many cystic fibrosis patients develop resistant infections  and mixed bacterial-fungal infections, both of which respond poorly to antibiotc therapy. Thus, there is a critical need for the development of new broad-spectrum antimicrobials that can be effectively used to treat resistant bacteria and fungi in cystic fibrosis  patients.

TGV-inhalonix has developed a breakthrough novel drug candidate to treat these chronic and often fatal infections. Recently granted Orphan Drug Designation by the U.S. Food and Drug Administration, its candidate, Mul-1867, is the first inhaled antimicrobial being developed against multidrug-resistant bacteria and fungi in cystic fibrosis patients.

TGV-inhalonix's New Drug to Help Save Cystic Fibrosis Patients w/ Resistant Fungal Lung Infections

TGV-inhalonix, a New York drug development company behind  ground-breaking Mul-1867 which gives hope to treating life-threatening, antibiotic-resistant bacterial lung infections in patients suffering from cystic fibrosis, announced that Mul-1867 has shown tremendous potential against clinical isolates of fungi from patients…

Login

Or using ePRNews Account

Don't have an account ? Sign Up

Register New Account

Or Signup using Email

Already have an account ? Login

Reset Password

Already have an account ? Login